Coated Solid Preparation

Abstract

The main object is to provide a novel pharmaceutical solid preparation containing a pharmaceutically active ingredient, wherein the solid preparation is coated with a light shielding agent in a nano-order thickness.

The present invention can include a pharmaceutical solid preparation containing at least one pharmaceutically active ingredient, wherein the surface of the solid preparation is coated with a light shielding agent or a metal oxide to a thickness in a range of 1 nm to 500 nm to form a coating layer, or is coated with a light shielding agent or a metal oxide which is present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2 to form a coating layer, and a process for producing a solid preparation containing at least one pharmaceutically active ingredient, comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation to a thickness in a range of 1 nm to 500 nm.

Claims

1-16. (canceled)

17. A pharmaceutical solid preparation containing at least one pharmaceutically active ingredient, wherein the surface of the solid preparation is coated with a light shielding agent or a metal oxide to form a coating layer, wherein a total amount of the light shielding agent and the metal oxide is from 5×10-6 mg/mm.sup.2 to 3×10-3 mg/mm.sup.2.

18. The pharmaceutical solid preparation according to claim 17, wherein the coating layer has a thickness from 1 nm to 500 nm.

19. The pharmaceutical solid preparation according to claim 17, wherein the coating layer comprises no polymer compound.

20. The pharmaceutical solid preparation according to claim 17, wherein the coating is performed by sputtering.

21. The pharmaceutical solid preparation according to claim 17, wherein the metal oxide is iron oxide or titanium oxide.

22. The pharmaceutical solid preparation according to claim 17, wherein the solid preparation is a tablet.

23. The pharmaceutical solid preparation according to claim 22, of which the disintegration time is substantially the same as that of the tablet before the coating.

24. A process for producing a solid preparation containing at least one pharmaceutically active ingredient, comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation in an amount of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2.

25. The process for producing a solid preparation according to claim 24, wherein the coating is made with a thickness in a range of 1 nm to 500 nm.

25. The process for producing a pharmaceutical solid preparation according to claim 24, wherein the metal oxide is iron oxide or titanium oxide.

26. The process for producing a pharmaceutical solid preparation according to claim 24, wherein the solid preparation is a tablet.

27. The process for producing a pharmaceutical solid preparation according to claim 26, of which the disintegration time is substantially the same as that of the tablet before the coating.

28. A method for photostabilizing a pharmaceutical solid preparation containing at least one pharmaceutically active ingredient, comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation in an amount of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2.

29. The method for photostabilizing a pharmaceutical solid preparation according to claim 28, wherein the coating is made with a thickness in a range of 1 nm to 500 nm.

30. The method for photostabilizing a pharmaceutical solid preparation according to claim 28, wherein the metal oxide is iron oxide or titanium oxide.

31. The method for photostabilizing a pharmaceutical solid preparation according to claim 28, wherein the solid preparation is a tablet.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 represents the results of photostability. The vertical axis indicates the amount generated (%) of the decomposition product I (described later), and the horizontal axis indicates the light irradiation amount (×10,000 Lux.Math.hr), respectively. Black triangles indicate the result of Example 1, black circles indicate the result of Example 2, black squares indicate the result of Example 3, cross marks indicate the result of Comparative Example 1 (uncoated plain tablets), and white circles indicate the result of Comparative Example 2 (film-coated tablets), respectively.

[0016] FIG. 2 represents the results of photostability. The vertical axis indicates the amount of decomposition product I generated (%) and the horizontal axis indicates the light irradiation amount (×10,000 Lux.Math.hr). Black squares indicate the result of Example 4, black circles indicate the result of Example 5, and cross marks indicate the result of Comparative Example 1 (uncoated plain tablets), respectively.

EMBODIMENT FOR CARRYING OUT THE PRESENT INVENTION

1 Pharmaceutical Solid Preparations According to the Present Invention

[0017] A pharmaceutical solid preparation according to the present invention (hereinafter, referred to as the “present invention preparation”) is a solid preparation containing at least one pharmaceutically active ingredient, wherein the surface of the solid preparation is coated with a light shielding agent or a metal oxide to a thickness in a range of 1 nm to 500 nm to form a coating layer. The present invention preparation is also a solid preparation containing at least one pharmaceutically active ingredient, wherein the surface of the solid preparation is coated with a light shielding agent or a metal oxide which is present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2 to form a coating layer.

[0018] In the present invention preparation, the pharmaceutically active ingredient is not particularly limited, as long as it is a medicine having pharmacological activity, but photolabile pharmaceutically active ingredients are preferred. Such active ingredients may include, for example, calcium antagonists such as Nifedipine, Amlodipine, Nicardipine, and Azelnidipine, and HMG-CoA reductase inhibitors such as vitamins, Atorvastatin, Pitavastatin, and Rosuvastatin.

[0019] In the present invention preparation, the light shielding agent or the metal oxide is not particularly limited, as long as it is pharmaceutically acceptable and can be sputtered, but metal oxides are suitable. The light shielding agent or the metal oxide used in the present invention can include iron oxides such as red ferric oxide, yellow ferric oxide, yellow iron oxide, and black iron oxide; silicon dioxide; and titanium oxide. Among them, yellow ferric oxide, red ferric oxide, and titanium oxide are preferred.

[0020] In the present invention, the light shielding agent or the metal oxide is coated (nanocoated) on the surface of the solid preparation with a thickness in a range of 1 nm to 500 nm to form a coating layer, and the thickness is preferably in a range of 5 nm to 400 nm, and more preferably in a range of 10 nm to 300 nm. If it is thinner than 1 nm, a sufficient light shielding effect may not be obtained, and if it is thicker than 500 nm, the manufacturing time may extend for a long time. Alternatively, in the present invention, the light shielding agent or the metal oxide is coated (nanocoated) on the surface of the solid preparation so as to be present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2 to form a coating layer, and the amount is preferably in a range of 2×10.sup.−5 mg/mm.sup.2 to 2×10.sup.−3 mg/mm.sup.2, and more preferably in a range of 5×10.sup.−5 mg/mm.sup.2 to 1.5×10.sup.−3 mg/mm.sup.2. If it is less than 5×10.sup.−6 mg/mm.sup.2, a sufficient light-shielding effect may not be obtained, and if it is more than 3×10.sup.−3 mg/mm.sup.2, the manufacturing time may extend for a long time.

[0021] As described above, since the light shielding agent or the metal oxide is coated on the nano-order in the present invention, for example, the disintegration time of the tablet before the coating (uncoated plain tablets, film-coated tablets, or the like) and the nanocoated tablet after the coating can be substantially the same. The term “substantially the same” as to the disintegration time herein means that the disintegration time of the nanocoated tablet after the coating is in a range of 0.5 to 1.5 times that of the tablet before the coating. It is preferably in a range of 0.8 to 1.2 times. The disintegration time can be measured according to the test method described in the Japanese Pharmacopoeia.

[0022] The dosage form of the present invention preparation is not particularly limited, as long as it is a pharmaceutical solid preparation, and examples thereof can include tablets, granules, powders, pellets, capsules, chewable tablets, troches, and film preparations. Among them, tablets are preferred. Tablets may be not only conventional tablets, but also multilayer tablets such as bilayer tablets and trilayer tablets, enteric coated tablets, sustained release tablets, so-called OD tablets such as orally disintegrating tablets, and OD films.

[0023] The nanocoating of the light shielding agent or the metal oxide is usually performed by sputtering. Sputtering itself is a known method, and the sputtering can be performed by the known method in the present invention, too. For example, a strong magnetic field is applied in a vacuum having a light shielding agent, argon is introduced into the vacuum, and ionized (Ar+) by the magnetic field, and atoms and molecules on the surface of the light shielding agent are ejected by causing the ionized argon to collide with the light shielding agent, and thereby the atoms and molecules reach the surface of the pharmaceutical solid preparation to be coated and are formed into a film. Apparatus for performing the sputtering is commercially available, and it is possible to perform the sputtering using them.

2 Process for Producing Pharmaceutical Solid Preparations According to the Present Invention

[0024] The process for producing a solid pharmaceutical preparation according to the present invention (hereinafter referred to as the “present invention process”) is a process for producing a pharmaceutical solid preparation containing at least one pharmaceutically active ingredient, characterized by comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation to a thickness in a range of 1 nm to 500 nm. The present invention process is also characterized by comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation so as to be present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2.

[0025] In the present invention process, first, a pharmaceutical solid preparation before the coating (uncoated plain tablets, film-coated tablets, or the like) is produced. Specifically, for example, a pharmaceutical solid preparation before the coating (e.g., uncoated plain tablets and film-coated tablets) is produced through steps of mixing at least one kind of pharmaceutically active ingredient with additives such as an excipient, a binder, a disintegrant, a stabilizer, and a colorant depending on the dosage form and the like, granulating, drying, sizing, adding a lubricant and the like, and tableting them, and if necessary, a step of film coating them with a coating agent containing a polymer, and other steps. Thereafter, the present invention process can be carried out by coating a light shielding agent or a metal oxide by sputtering on the surface of the pharmaceutical solid preparation before the coating (uncoated plain tablets, film-coated tablets, etc.) to a thickness in a range of 1 nm to 500 nm (preferably 5 nm to 400 nm, and more preferably 10 nm to 300 nm), or so as to be present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2 (preferably 2×10.sup.−5 mg/mm.sup.2 to 2×10.sup.−3 mg/mm.sup.2, and more preferably 5×10.sup.−5 mg/mm.sup.2 to 1.5×10.sup.−3 mg/mm.sup.2).

[0026] The meanings of the pharmaceutically active ingredient, the solid preparation, the sputtering, the light shielding agent, the metal oxide, and the like in the present invention process are the same as described above.

[0027] Excipients used in the present invention can include lactose, starch (e.g., corn starch, potato starch, rice starch, and wheat starch), crystalline cellulose, D-mannitol, dextrin, sorbitol, calcium phosphate anhydride, white sugar, talc (natural hydrous magnesium silicate), kaolin, precipitated calcium carbonate, sodium chloride, titanium oxide, and light anhydrous silicic acid, for example.

[0028] Binding agents used in the present invention can include hydroxypropyl cellulose, hypromellose (hydroxypropyl methylcellulose, HPMC), microcrystalline cellulose, dextrin, tragacanth, gelatin, alphaized starch, gum arabic, acacia, alginic acid, carboxymethyl cellulose, ethyl cellulose, methylcellulose, hydroxyethyl cellulose, ethyl hydroxyethyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylate, carboxymethyl cellulose calcium, and sodium carboxymethyl cellulose, for example.

[0029] Stabilizing agents used in the present invention can include butylhydroxytoluene (BHT), propyl gallate, butylhydroxyanisole (BHA), lecithin, α-tocopherol, hydroquinone, octyl gallate, dodecyl gallate, isoamyl gallate, nordihydroguaiaretic acid, guaiac fat, α-naphthylamine, ascorbate palmitate, cysteine hydrochloride, sodium stearate ascorbate, thioglycerol, and thiosorbitol, for example.

[0030] Disintegrants used in the present invention can include croscarmellose sodium, crospovidone, alginic acid, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone, sodium alginate, sodium starch glycolate, partially hydrolyzed starch, and an agar powder, for example.

[0031] Lubricants used in the present invention can include magnesium stearate, calcium stearate, talc, mineral oil, stearic acid, fumaric acid, polyethylene glycol, calcium, boric acid, paraffin, and cocoa butter, for example.

[0032] Pigments used in the present invention can include tar dye, red ferric oxide, red iron oxide, yellow iron oxide, titanium dioxide, inorganic dye, red No. 3, red No. 20, yellow No. 6, blue No. 2, green No. 5, orange No. 5, red No. 8, and caramel which can be used in pharmaceuticals and the like, as stipulated by the Ministry of Health, Labor and Welfare ordinance, for example.

[0033] Each of the above additives may be used either alone or in combination of one or any two or more kinds thereof. Further, each of them can be used in an appropriate amount as needed.

[0034] According to the present invention process, since the light shielding agent or the metal oxide is coated in the nano-order on the tablet before the coating (uncoated plain tablets, film-coated tablets, or the like), it is possible to produce the tablet having substantially the same disintegration time as that of the tablet before the coating.

3 Photostablizing Methods for Pharmaceutical Solid Formulations

[0035] The method for photostabilizing a pharmaceutical solid preparation according to the present invention (hereinafter referred to as the “photostabilization method of the present invention”) is a method for photostabilizing a solid preparation containing at least one pharmaceutically active ingredient, characterized by comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation to a thickness in a range of 1 nm to 500 nm. The photostabilization method of the present invention is also characterized by comprising a step of coating a light shielding agent or a metal oxide by sputtering on the surface of the solid preparation so as to be present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2.

[0036] The photostabilization method of the present invention can be carried out at least by coating a light shielding agent or a metal oxide by sputtering on the surface of the pharmaceutical solid preparation such as tablets to a thickness in a range of 1 nm to 500 nm (preferably 5 nm to 400 nm, and more preferably 10 nm to 300 nm), or so as to be present in a range of 5×10.sup.−6 mg/mm.sup.2 to 3×10.sup.−3 mg/mm.sup.2 (preferably 2×10.sup.−5 mg/mm.sup.2 to 2×10.sup.−3 mg/mm.sup.2, and more preferably 5×10.sup.−5 mg/mm.sup.2 to 1.5×10.sup.−3 mg/mm.sup.2).

[0037] The meanings of the pharmaceutically active ingredient, the solid preparation, the sputtering, the light shielding agent, the metal oxide, and the like in the photostabilization method of the present invention are the same as described above.

Example

[0038] Hereinafter, the present invention will be described with reference to Examples, Comparative Examples, Test Examples, and the like, but the present invention is not limited by these Examples and the like in any way.

[Comparative Example 1, Examples 1 to 3] Preparations of Uncoated Plain Tablets and Nanocoated Tablets with Red Ferric Oxide

[0039] In accordance with the formulations in Tables 1 and 2 below, the uncoated plain tablet of Comparative Example 1 and the tablets of Examples 1 to 3, the present invention preparations, were prepared by being nanocoated with red ferric oxide to a thickness of about 10 nm to 300 nm or so that the red ferric oxide is present in 5.23×10.sup.−5 mg/mm.sup.2 to 1.57×10.sup.−3 mg/mm.sup.2.

TABLE-US-00001 TABLE 1 Blending amount (mg) Comp. Example 1, Composition Ingredient Examples 1 to 3 (A) active granules Amlodipine besilate 6.93 excipient 52.87 pigment 0.2 (A) active granules total 60 (B) fast disintegrating excipient 130.8 granules disintegrant 3.6 pigment 0.2 (B) fast disintegrating granules total 134.6 (C) flavoring granules excipient 1.7 taste modifier 0.5 (C) flavoring granules total 2.2

TABLE-US-00002 TABLE 2 Blending amount (mg) Comp. Examples Composition Ingredient Example 1 1 to 3 Tablet (A) active granules 60 60 (B) fast disintegrating 134.6 134.6 granules (C) flavoring granules 2.2 2.2 lubricant 1.9 1.9 sweeting agent 5.3 5.3 perfume 1 1 Tablet total 205 205 Coating red ferric oxide — trace (*) Total 205 205 (*) Example 1 (10 nm in film thickness): 0.009 mg/tablet, 5.23 × 10.sup.−5 mg/mm.sup.2 Example 2 (30 nm in film thickness): 0.027 mg/tablet, 1.57 × 10.sup.−4 mg/mm.sup.2 Example 3 (300 nm in film thickness): 0.27 mg/tablet, 1.57 × 10.sup.−3 mg/mm.sup.2

[0040] Specifically, the uncoated plain tablet of Comparative Example 1 and the red ferric oxide-nanocoated tablets of Examples 1 to 3 were produced as follows.

(1) Preparation of Tablets

[0041] (A) Active granules, (B) fast disintegrating granules, (C) sweetening agent granulated into flavoring granules, and perfume were placed in a diffusion type mixer and mixed, and then a granulated lubricant was added and further mixed to obtain a tablet powder. The tablet of Comparative Example 1 was obtained by tableting the tablet powder so as to have a punch diameter of 8.5 mm and a tablet mass of 205 mg.

(2) Nanocoating: Preparation of Tablets of Examples 1 to 3

[0042] The tablet (uncoated plain tablet) of Comparative Example 1 was coated with a predetermined amount of red ferric oxide using a magnetron type sputtering apparatus (product number: L560, manufactured by Leybold Co.) to produce the nanocoated tablets of Examples 1 to 3 of the present invention preparation.

[Comparative Example 2] Film-Coated Tablets

[0043] A mixture of TC-5 (hypromellose, 5.7 mg/tablet) and red ferric oxide (0.027 mg/tablet) was prepared, with which the tablet of Comparative Example 1 was film-coated by a conventional method to produce the film-coated tablet of Comparative Example 2.

[Test Example 1] Physical Properties of Tablets

[0044] Physical properties of the obtained tablets of Examples 1 to 3 and Comparative Examples 1 and 2 were measured by a conventional method (n=3). The results are shown in Table 3 below.

TABLE-US-00003 TABLE 3 Comp. Comp. Example 1 Example 2 Example 3 Example 1 Example 2 Coating method sputtering sputtering sputtering — film coating Thickness of layer 10 nm 30 nm 300 nm — 0.12 mm Coating amount of 0.009 0.027 0.27 0 0.027 Fe.sub.2O.sub.3 (mg/tablet) Hardness (N) 59 63 63 73 131 Disintegration 20 18 21 19 86 time (s)

[0045] As is apparent from Table 3, all of the present invention preparations of Examples 1 to 3 had a disintegration time faster than that of a conventional film-coated tablet (Comparative Example 2) and almost equivalent to that of an uncoated plain tablet (Comparative Example 1), and had excellent disintegration properties.

[Test Example 2] Photostability Test

[0046] The tablets of Examples 1 to 3 and Comparative Examples 1 and 2 were placed in a photostability tester, and a photostability test was performed by a xenon lamp irradiation with 0.3 to 1.2 million lx.Math.hr under a condition of 70% RH at 25° C. The results are shown in Table 5 and FIG. 1. The amount of the decomposition product I having the following structural formula was measured by high performance liquid chromatography (HPLC). The measurement conditions are as follows.

##STR00001##

[HPLC Measurement Conditions]

[0047] Detector: Waters2487, ultraviolet absorption photometer (measured at 237 nm) [0048] Column: Cadenza CD C18, A stainless steel column having an inner diameter of 4.6 mm and a length of 15 cm, packed with octylsilanized silica gel for liquid chromatography (3 μm in particle diameter). [0049] Column temperature: A constant temperature around 35° C. [0050] Sample temperature: A constant temperature around 4° C. [0051] Mobile phase: A mixed solution of potassium dihydrogen phosphate aqueous solution and acetonitrile

TABLE-US-00004 TABLE 4 Potassium dihydrogen phosphate Time (min) aqueous solution (%) Acetonitrile (%)  0 to 15 80 .fwdarw. 50 20 .fwdarw. 50 15 to 20 50 .fwdarw. 20 50 .fwdarw. 80 20 to 25 20 80 25 to 26 20 .fwdarw. 80 80 .fwdarw. 20 26 to 30 80 20 [0052] Flow rate: 1.0 mL/min [0053] Analysis time: 30 minutes

TABLE-US-00005 TABLE 5 Comp. Comp. Example 1 Example 2 Example 3 Example 1 Example 2 Coating method sputtering sputtering sputtering — film coating Coating amount of Fe.sub.2O.sub.3 0.009 0.027 0.27 0 0.027 (mg/tablet) Photostability 0 Decomp. 0.09 0.10 0.12 0.08 0.10 test 30 product I 0.34 0.33 0.17 0.78 0.39 (×10.sup.4 lx .Math. hr) 60 (%) 0.60 0.45 0.16 1.05 0.61 120 1.18 0.72 0.22 1.67 1.13

[0054] As is apparent from Table 5 and FIG. 1, all of the present invention preparations of Examples 1 to 3 were excellent in photostability, which was superior to that of the uncoated plain tablet of Comparative Example 1, and equivalent to or higher than that of the conventional film-coated tablet of Comparative Example 2. With only a 30 nm coating of red ferric oxide (Example 2), the increase in the photodecomposition product was halved from that of the uncoated plain tablet of Comparative Example 1. In addition, as is apparent from the comparison of Example 2 and Comparative Example 2, in which the coating amount of red ferric oxide is the same, the present invention has a smaller amount of increase in photolysate than a conventional film coating and is excellent in photostability.

[Examples 4 and 5] Preparation of Nanocoated Tablets by Titanium Oxide

[0055] The uncoated plain tablet of Comparative Example 1, and the tablets of Examples 4 and 5, the present invention preparations, nanocoated with titanium oxide to a thickness of about 30 nm or 300 nm or so that titanium oxide is present in 1.2×10.sup.−4 mg/mm.sup.2 or 1.2×10.sup.−3 mg/mm.sup.2 were prepared according to the formulation of Table 6 below.

TABLE-US-00006 TABLE 6 Blending amount (mg) Composition Ingredient Examples 4, 5 Tablet (A) active granules 60 (B) fast disintegrating 134.6 granules (C) flavoring granules 2.2 lubricant 1.9 sweeting agent 5.3 perfume 1 Tablet total 205 Coating titanium oxide trace (**) Total 205 (**) Example 4 (30 nm in film thickness): 0.0205 mg/tablet, 1.2 × 10.sup.−4 mg/mm.sup.2 Example 5 (300 nm in film thickness): 0.205 mg/tablet, 1.2 × 10.sup.−3 mg/mm.sup.2

[0056] Specifically, the uncoated plain tablet of Comparative Example 1 was coated with a predetermined amount of titanium oxide using a magnetron type sputtering apparatus (product number: L560, manufactured by Leybold Co.) to produce the nanocoated tablets of Examples 4 and 5 of the present invention preparation.

[Test Example 3] Physical Properties of Tablets

[0057] Physical properties of the obtained tablets of Examples 4 and 5, and Comparative Example 1 were measured by a conventional method (n=3). The results are shown in Table 7 below.

TABLE-US-00007 TABLE 7 Comp. Example 4 Example 5 Example 1 Thickness of layer 30 nm 300 nm — Coating amount of TiO.sub.2 0.0205 0.205 0 (mg/tablet) Hardness (N) 51 52 73 Disintegration time (s) 20 20 19

[0058] As is apparent from Table 7, all of the present invention preparations of Examples 4 and 5 had almost the same disintegration time as that of the uncoated plain tablet (Comparative Example 1), and were excellent in disintegration properties.

[Test Example 4] Photostability Test

[0059] The tablets of Examples 4 and 5 were placed in a photostability tester, and a photostability test was performed by a xenon lamp irradiation with 0.3 to 1.2 million lx.Math.hr under 70% RH conditions at 25° C. The results are shown in Table 8 and FIG. 2. Under the same measurement conditions as in Test Example 2 described above, the amount of the decomposition product I was measured by high performance liquid chromatography (HPLC).

TABLE-US-00008 TABLE 8 Comp. Example 4 Example 5 Example 1 Coating amount of TiO.sub.2 0.0205 0.205 0 (mg/tablet) Photostability 0 Decomp. 0.10 0.11 0.08 test 30 product I 0.47 0.34 0.78 (×10.sup.4 lx .Math. hr) 60 (%) 0.66 0.58 1.05 120 1.35 0.99 1.67

[0060] As is apparent from Table 8 and FIG. 2, all of the present invention preparations of Examples 4 and 5 exhibited higher photostability than that of the uncoated plain tablet of Comparative Example 1. Even with only a 30 nm coating of titanium oxide (Example 4), the increase of the photolysate amount is greatly suppressed as compared with the uncoated plain tablet of Comparative Example 1.

INDUSTRIAL APPLICABILITY

[0061] According to the present invention, for example, it is possible to provide a pharmaceutical solid preparation having excellent disintegration properties while ensuring photostability of a medicine, and therefore the present invention is useful in a pharmaceutical solid preparation containing an active ingredient which is unstable to light, or useful in the production thereof.